A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.

<h4>Background</h4>Allogeneic hematopoietic stem cell transplantation (HCT) is an often curative intent treatment, however it is associated with significant gastrointestinal (GI) toxicity and treatment related mortality. Graft-versus-host disease is a significant contributor to transplan...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sendhilnathan Ramalingam, Sharareh Siamakpour-Reihani, Lauren Bohannan, Yi Ren, Alexander Sibley, Jeff Sheng, Li Ma, Andrew B Nixon, Jing Lyu, Daniel C Parker, James Bain, Michael Muehlbauer, Olga Ilkayeva, Virginia Byers Kraus, Janet L Huebner, Thomas Spitzer, Jami Brown, Jonathan U Peled, Marcel van den Brink, Antonio Gomes, Taewoong Choi, Cristina Gasparetto, Mitchell Horwitz, Gwynn Long, Richard Lopez, David Rizzieri, Stefanie Sarantopoulos, Nelson Chao, Anthony D Sung
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f83a9f8874344c358e65b574f37f7011
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.

Ejemplares similares